Hospitals accounted for a 60.92% share of the catastrophic antiphospholipid syndrome market in 2025, reflecting their central role in managing this acute and highly complex condition. Leadership in this end-use segment is sustained by the need for rapid multidisciplinary intervention, intensive monitoring, and access to critical care infrastructure that hospitals are equipped to provide. Since catastrophic antiphospholipid syndrome often involves severe thrombotic complications across multiple organ systems, hospital settings remain the primary point of care where emergency treatment pathways, specialist coordination, and advanced supportive services can be delivered without delay.

Clinics are emerging as the fastest-growing end-use segment in the catastrophic antiphospholipid syndrome market as care pathways increasingly extend beyond acute inpatient treatment into follow-up management and ongoing monitoring. Their momentum is supported by the practical need for more accessible specialist consultations, therapy supervision, and post-hospital care coordination, particularly for patients requiring continued assessment after stabilization. Compared with hospitals, clinics are experiencing stronger uptake where structured outpatient management can improve continuity of care while reducing the burden on high-acuity facilities.

Treatment Segment Analysis: Intravenous Immunoglobulin (IVIG) (Largest Segment) vs Plasma Exchange Therapy (Plasmapheresis) (Fastest-Growing Segment)

In 2025, Intravenous Immunoglobulin (IVIG) held a 39.15% share of the catastrophic antiphospholipid syndrome market, making it the leading treatment segment. Its position is supported by its established use within combination treatment approaches for severe immune-mediated episodes, especially in settings where clinicians need therapies that can be integrated into urgent hospital-based management. IVIG maintains leadership in the catastrophic antiphospholipid syndrome market because it fits practical treatment protocols for critically ill patients and can be deployed within the broader effort to control immune dysregulation and limit further clinical deterioration.

Plasma Exchange Therapy (Plasmapheresis) is the fastest-growing treatment segment in the catastrophic antiphospholipid syndrome market, driven by its role in addressing the underlying pathogenic factors associated with rapidly progressing disease. Growth is being supported by increasing clinical reliance on treatment strategies that can remove circulating harmful components in acute cases where fast intervention is essential. Relative to alternatives, plasmapheresis is gaining momentum because it aligns closely with the urgency and severity profile of catastrophic antiphospholipid syndrome, particularly when treatment escalation is required in intensive care settings.